"to be honest, that was what i had almost expected," she said.. in washington before heading to baltimore for saturday's broadcast of.
why novartis� landmark cancer drug approval is great news for bluebird.
the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid..
"i can't think of anything else where we have done that medically," van den veyver said..